Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality. Although clinical resistance to PARPi has been described, the mechanism underlying this has not been elucidated. Here, we in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pathology 2013-02, Vol.229 (3), p.422-429
Hauptverfasser:	Barber, Louise J, Sandhu, Shahneen, Chen, Lina, Campbell, James, Kozarewa, Iwanka, Fenwick, Kerry, Assiotis, Ioannis, Rodrigues, Daniel Nava, Reis-Filho, Jorge S, Moreno, Victor, Mateo, Joaquin, Molife, L Rhoda, De Bono, Johann, Kaye, Stan, Lord, Christopher J, Ashworth, Alan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - secondary Antineoplastic Agents - pharmacology BRCA BRCA2 Protein - genetics Breast Neoplasms, Male - drug therapy Breast Neoplasms, Male - genetics Breast Neoplasms, Male - pathology cancer Combined Modality Therapy DNA Mutational Analysis drug resistance Drug Resistance, Neoplasm Female Gene Expression Regulation, Neoplastic - drug effects Humans Male massively parallel sequencing Middle Aged Mutation Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology PARP inhibitor Phthalazines - pharmacology Piperazines - pharmacology Poly(ADP-ribose) Polymerase Inhibitors secondary mutation Sequence Analysis, DNA
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!